文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

美国心脏骤停后死亡率和医疗资源利用:COVID-19大流行前10年全国性分析

Mortality and healthcare resource utilisation after cardiac arrest in the United States - A 10-year nationwide analysis prior to the COVID-19 pandemic.
PubMed 文献 · Resuscitation · 2023-08-25
一句话结论2010至2019年美国成人心脏骤停院内死亡率从58.3%降至46.4%,住院时间缩短11%但费用增加13%,机械循环支持使用显著增加,年龄和种族差异显著。

该研究利用美国全国住院患者样本(NIS)数据库,纳入2010至2019年间248,754例无心肺复苏禁忌的成人心脏骤停患者,采用logistic和Poisson回归调整47个混杂因素分析结局。结果显示院内死亡率为51.2%,从2010年的58.3%显著改善至2019年的46.4%(P<0.001);平均住院时间缩短11%,但住院费用增加13%(各P<0.001),推测与机械循环支持使用增加有关(ECMO从2.6%升至8.7%,Impella®微轴流泵从1.8%升至14.2%)。研究还发现老年、非白人及需要复杂治疗的患者死亡率更高,不同年龄组和种族间存在显著差异,年轻成人及阿片类药物诱发的心脏骤停数量几乎翻倍。

要点

  • 2010至2019年美国成人心脏骤停院内死亡率从58.3%降至46.4%(P<0.001),总体死亡率为51.2%。
  • 平均住院时间缩短11%,但住院费用增加13%(各P<0.001),可能与机械循环支持使用增加有关。
  • ECMO使用率从2.6%升至8.7%,Impella®微轴流泵使用率从1.8%升至14.2%。
  • 老年、非白人及需要复杂治疗的患者死亡率更高;年轻成人及阿片类药物诱发的心脏骤停数量几乎翻倍。
  • 作者认为应考虑建立国家心脏骤停监测标准,以识别治疗趋势和差异,实现标准化医疗。

适用人群与场景

  • 美国全国住院成人心脏骤停患者,排除有「Do Not Resuscitate」医嘱者,数据来源于2010至2019年美国全国住院患者样本(NIS)。

研究设计与关键结果

  • 研究类型:基于美国全国住院患者样本(NIS)的回顾性分析,纳入248,754例成人心脏骤停患者,57.5%为男性。
  • 主要终点:院内死亡率为51.2%,从2010年的58.3%显著改善至2019年的46.4%(P<0.001)。
  • 住院时间与费用:平均住院时间缩短11%,住院费用增加13%(各P<0.001)。
  • 机械循环支持使用:ECMO从2.6%升至8.7%,Impella®微轴流泵从1.8%升至14.2%。
  • 差异:老年、非白人及需要复杂治疗的患者死亡率更高;不同年龄组和种族间存在显著差异。
  • 趋势:年轻成人心脏骤停及阿片类药物诱发的心脏骤停数量几乎翻倍。

证据类型、等级与局限

  • 证据类型:基于全国住院患者样本(NIS)的回顾性分析,采用logistic和Poisson回归调整47个混杂因素。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为应考虑建立国家心脏骤停监测标准,以识别心脏骤停治疗的趋势和差异,实现标准化医疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: Understanding the public health burden of cardiac arrest (CA) is important to inform healthcare policies, particularly during healthcare crises such as the COVID-19 pandemic. This study aimed to analyse outcomes of in-hospital mortality and healthcare resource utilisation in adult patients with CA in the United States over the last decade prior to the COVID-19 pandemic.

METHODS: The United States (US) National Inpatient Sample was utilised to identify hospitalised adult patients with CA between 2010 and 2019. Logistic and Poisson regression models were used to analyse outcomes by adjusting for 47 confounders.

RESULTS: 248,754 adult patients with CA (without "Do Not Resuscitate"-orders) were included in this study, out of which 57.5% were male. In-hospital mortality was high with 51.2% but improved significantly from 58.3% in 2010 to 46.4% in 2019 (P < 0.001). Particularly, elderly patients, non-white patients and patients requiring complex therapy had a higher mortality rate. Although the average hospital LOS decreased by 11%, hospital expenses have increased by 13% between 2010 and 2019 (each P < 0.001), presumably due to more frequent use of mechanical circulatory support (MCS, e.g. ECMO from 2.6% to 8.7% or Impella® micro-axial flow pump from 1.8% to 14.2%). Strong disparities existed among patient age groups and ethnicities across the US. Of note, the number of young adults with CA and opioid-induced CA has almost doubled within the study period.

CONCLUSION: Over the last ten years prior to the COVID-19 pandemic, CA-related survival has incrementally improved with shorter hospitalisations and increased medical expenses, while strong disparities existed among different age groups and ethnicities. National standards for CA surveillance should be considered to identify trends and differences in CA treatment to allow for standardised medical care.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Thevathasan T, Paul J, Gaul AL, et al. Mortality and healthcare resource utilisation after cardiac arrest in the United States - A 10-year nationwide analysis prior to the COVID-19 pandemic. Resuscitation. 2023. PMID: 37634860. doi:10.1016/j.resuscitation.2023.109946

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。